Delivering the right drugs to the right place at the right time has always been a challenge for the biopharmaceutical industry. Peptineo LLC aims to meet that challenge by developing and commercializing nanoscale technologies and materials for drug delivery and drug discovery. Its aim is to improve the delivery of drugs in development, extend the life cycle of marketed drugs, and repurpose existing or failed compounds.
Peptineo LLC
609 Broadway Boulevard NE
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
